口服托法替布治疗克罗恩病患者的长期安全性和耐受性:一项2期开放标签48周扩展研究的结果
本48周开放标签扩展研究主要评估托法替布5 mg和10 mg每日两次的长期安全性,次要评估其作为克罗恩病维持治疗的疗效。共62例接受5 mg每日两次、88例接受10 mg每日两次;两组总体不良事件和严重感染率相似,但10 mg组严重不良事件更常见;基线缓解者接受5 mg每日两次第48周维持缓解率为87.9%。
要点
- 托法替布5 mg与10 mg每日两次总体不良事件和严重感染率相似。
- 10 mg每日两次组严重不良事件(19.3%)高于5 mg每日两次组(8.1%)。
- 基线缓解者接受5 mg每日两次第48周维持缓解率为87.9%。
核心结论
- 未出现新的安全性信号;尽管两剂量总体不良事件相似,托法替布10 mg每日两次的严重不良事件比5 mg每日两次更常见。
- 因临床应答不足而停药在基线缓解的患者中较低。
研究设计与样本
- 48周开放标签扩展研究,纳入完成2b期维持研究或因治疗失败而退出的克罗恩病患者。
- 基线缓解(克罗恩病活动指数<150)者接受托法替布5 mg每日两次,其余接受10 mg每日两次;固定开放标签治疗8周后允许单次剂量调整。
- 62例接受托法替布5 mg每日两次,88例接受10 mg每日两次;研究设计阻止了剂量间疗效比较。
主要发现
- 克罗恩病加重是托法替布5 mg(33.9%)和10 mg每日两次(19.3%)最常见的不良事件。
- 基线未缓解且接受10 mg每日两次的患者严重不良事件发生率为19.3%,因临床应答不足停药率为30.7%。
- 基线未缓解且接受5 mg每日两次的患者严重不良事件发生率为8.1%,因临床应答不足停药率为9.7%。
- 第48周时,基线缓解且接受5 mg每日两次的患者中87.9%维持缓解、75.0%持续缓解(按观察值);按无应答者填补分别为46.8%和38.7%。
局限性
- 研究设计阻止了剂量间疗效比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor that is being investigated for inflammatory bowel disease. AIMS: This 48-week open-label extension study primarily investigated long-term safety of tofacitinib 5 and 10 mg b.d. and secondarily investigated efficacy as maintenance therapy in patients with Crohn's disease. METHODS: Patients who had completed the phase 2b maintenance study, or withdrawn due to treatment failure, were enrolled. Patients in remission (Crohn's disease activity index <150) at baseline received tofacitinib 5 mg b.d.; all others received 10 mg b.d. A single dose adjustment was allowed after 8 weeks' fixed, open-label treatment. RESULTS: Sixty-two patients received tofacitinib 5 mg b.d.; 88 received 10 mg b.d. Both groups had similar rates of adverse events and serious infections. Crohn's disease worsening was the most frequent adverse event for tofacitinib 5 (33.9%) and 10 mg b.d. (19.3%). Patients not in remission at baseline, receiving 10 mg b.d., had higher rates of serious adverse events (19.3%) and discontinuation attributed to insufficient clinical response (30.7%) vs 5 mg b.d. (8.1% and 9.7%, respectively). At week 48, of patients with baseline remission receiving 5 mg b.d., 87.9% maintained remission and 75.0% sustained remission as observed (46.8% and 38.7%, respectively, by non-responder imputation). Study design prevented between-dose efficacy comparisons. CONCLUSIONS: No new safety signals emerged. Although both doses showed generally similar safety outcomes for overall adverse events, serious adverse events were more frequent for tofacitinib 10 than 5 mg b.d. Discontinuation due to insufficient clinical response was lower among patients in remission at baseline. ClinicalTrials.gov: NCT01470599.
引用
- Panés J, D'Haens GR, Higgins PDR, et al. Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. Aliment Pharmacol Ther. 2019. PMID: 30663107. doi:10.1111/apt.15072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。